Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Methylprednisolone Acetate

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Suspension) Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 13, 2026, 11:29 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Methylprednisolone Acetate

Methylprednisolone Acetate

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Liquid (Suspension) Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Methylprednisolone Acetate

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs. Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats. Treatment of inflammation and related disorders in horses. Species commonly shown: Both, Dog, Restricted During Pregnancy, Horse, Restricted During Pregnancy.

Generic name
Methylprednisolone Acetate
Brand names
Methylprednisolone Acetate Inj., Medrol® Tablets, Depo-Medrol®, Methylprednisolene Tablets
Manufacturer
Multiple FDA labelers
Species
Both, Dog, Horse, Cat
Dosage forms
Liquid (Suspension), Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Methylprednisolone Acetate Inj. Medrol® Tablets Depo-Medrol® Methylprednisolene Tablets Medrol Depo-Medrol methylprednisolone
Dosage forms
Liquid (Suspension) Tablet

Indications / Uses

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs. Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats. Treatment of inflammation and related disorders in horses.

Warnings / Contraindications

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

  • Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

Side Effects

Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Weight loss, Diarrhoea.

FAQ

Both, Dog, Restricted During Pregnancy, Horse, Restricted During Pregnancy, Horse, Not For Meat Production, Cat, Restricted During Pregnancy, Restricted During Pregnancy

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Tablet

Related Conditions

Congestive heart failure Corneal ulcer Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus (Canine) Dystocia Metritis Pain (acute, chronic)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For use in dogs as an anti-inflammatory agent.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Not for human use
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome
  • The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids
  • Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions
  • Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic
  • Appropriate antibacterial therapy should be instituted immediately
  • Not for use in horses intended for food
  • Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,
  • Haematuria (1 reports)
  • Gut sounds increased (1 reports)
  • Glucosuria (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Methylprednisolone Acetate; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-074210
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 21 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-074210
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-074210
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Haematuria (1 reports), Gut sounds increased (1 reports), Glucosuria (1 reports), Gastroenteritis (1 reports), Gastritis (1 reports)

Body systems represented Signal grouping

Digestive (4), Skin & allergy (2), Neurologic (2), Behavior (1)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (17 reports), Cat (15 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (4), Catahoula Leopard Dog (1), ['Akita', 'Dog (unknown)'] (1), Beagle (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Methylprednisolone Acetate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Not for human use, Clinical and experimental data have demonstrated that corticosteroids administered orally or parente, Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in an, The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predispos, Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindi

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Methylprednisolone Acetate brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-074210 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. SPL · document · documents
  7. SPL · document · documents
  8. SPL · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Not for human use
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome
  • The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids
  • Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions

Most reported reactions:

  • Haematuria (1 reports)
  • Gut sounds increased (1 reports)
  • Glucosuria (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat, Dog, Horse, Restricted During Pregnancy
Indication / use
For use in dogs as an anti-inflammatory agent.
Form / route / dose
Form: Liquid (Suspension), Tablet
Route: Intramuscular, Intrasynovial, Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and e…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Liquid (Suspension), Tablet
Identifiers:
NADA: 11403 NADA: 12204 NADA: 135771 NADA: 136212 NDC Package: 54771-1613-1 NDC Package: 54771-1614-1 NDC Package: 54771-3547-1 NDC Package: 69043-042-10 NDC Product: 54771 NDC Product: 69043
Source metadata:

Warnings / Contraindications

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

  • High: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
7
Matching reports
0
Active filters
2
Selected filters
Reaction: Abnormal cytology Clear Body system: Behavior Clear
Reset
Drill into common report signals
Diarrhoea (2) Abnormal cytology (1) Behavioural disorder NOS (1) Biting - pruritus (see also Behavioural disorders) (1) Other (5) Digestive (2) Skin & allergy (2) Behavior (1)
No stored openFDA reports match the selected filters. openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
21
Species represented
2
Grouped by Body System
Digestive (4) · Diarrhea, Decreased appetite, Bloody diarrhoea Skin & allergy (2) · Biting - pruritus, Alopecia local Neurologic (2) · Unsteady walking (ataxia), Head tilt - neurological disorder Behavior (1) · Behavioral disorder (unspecified) Other (23) · Hiding, Haematuria, Gut sounds increased
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (17) Cat (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Non-serious - 1
Other Cat Non-serious - 1
Neurologic Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Digestive Dog Serious - 1
Skin & allergy Cat Non-serious - 1
Behavior Dog Non-serious - 1
Other Cat Serious - 1
Skin & allergy Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Medrol® Tablets SPL · SPL Methylprednisolene Tablets SPL · SPL Depo-Medrol® SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

7

FOI

0
No FOI links yet.

Medrol® Tablets

SPL · SPL

Open original
FDA Structured Product Label

Medrol® Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
11403
Status
RX
Form
Tablet
Route
Oral
Species
Dog • Cat
Composition / specifications
Each tablet contains 1 or 4 milligrams of methylprednisolone.

Dogs

Indication
For use in dogs as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

Cats

Indication
For use in cats as an anti-inflammatory agent.
Dosage
5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.
Limitations
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

Methylprednisolene Tablets

SPL · SPL

Open original
FDA Structured Product Label

Methylprednisolene Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
NADA
135-771
Status
RX
Form
Tablet
Route
Oral
Species
Dog • Cat
Composition / specifications
Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.

Dogs

Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations
Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

Cats

Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.

Depo-Medrol®

SPL · SPL

Open original
FDA Structured Product Label

Depo-Medrol®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
12204
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intrasynovial
Species
Dog • Restricted During Pregnancy • Cat
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication
Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Cats

Indication
Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Horses

Indication
Treatment of inflammation and related disorders in horses.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Methylprednisolone Acetate Inj.

SPL · SPL

Open original
FDA Structured Product Label

Methylprednisolone Acetate Inj.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
NADA
136-212
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intrasynovial
Species
Dog • Horse • Cat
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.

Dogs

Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Or up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Cats

Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Horses

Indication
Treatment of inflammation and related disorders.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Depo-Medrol SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Depo-Medrol. Use the source link for the full official labeling record.

Medrol SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Medrol. Use the source link for the full official labeling record.

methylprednisolone SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for methylprednisolone. Use the source link for the full official labeling record.
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Depo-Medrol Medrol methylprednisolone
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog, Horse, Restricted During Pregnancy
Rx/OTC: RX
Form/route: Liquid (Suspension), Tablet • Intramuscular, Intrasynovial, Oral
Applications: NADA 11403 • NADA 135-771 • NADA 12204 • NADA 136-212
NDC: Packages 54771-1613-1 54771-1614-1 54771-3547-1 69043-042-10 • Products 54771 69043
Documents: • SPL: 4 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 9 • Cat 11 • View
Case summaries: 7 (showing 7) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: E11.9
Type 2 diabetes mellitus without complications

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, (Contraindication, High)
Top reaction signals
Haematuria (1) Gut sounds increased (1) Glucosuria (1) Gastroenteritis (1) Gastritis (1) Excessive chewing, licking and/or grooming (1) Eosinopenia (1) Elevated blood urea nitrogen (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 11403 NADA: 12204 NADA: 135771 NADA: 136212 NDC Package: 54771-1613-1 NDC Package: 54771-1614-1 NDC Package: 54771-3547-1 NDC Package: 69043-042-10 NDC Product: 54771 NDC Product: 69043
Package NDC Product NDC Form / Route Status
54771-1613-1 54771 -
54771-1614-1 54771 -
54771-3547-1 54771 -
69043-042-10 69043 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Depo-Medrol SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Medrol SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • methylprednisolone SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 122 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Weight l… (Clinical, 2026-04-11)
  • contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-04-12)
  • contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-04-11)
  • contraindications: Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that … (Official, 2026-02-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-21)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-20)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-13)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-11)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-11)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-10)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-09)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-08)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-07)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-06)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-05)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-04)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Medrol® Tablets
RX
Methylprednisolone
Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 11403 Approved Feb 23, 2024
Methylprednisolene Tablets
RX
Methylprednisolone
Tablet • Oral
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. NADA 135-771 Approved Nov 24, 2023
Depo-Medrol®
RX
Methylprednisolone Acetate
Liquid (Suspension) • Intramuscular, Intrasynovial
Label highlights
Official documents
Zoetis Inc. NADA 12204 Approved Dec 7, 2021
Methylprednisolone Acetate Inj.
RX
Methylprednisolone Acetate
Liquid (Suspension) • Intramuscular, Intrasynovial
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. NADA 136-212 Approved Feb 1, 2018

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog • Cat
Composition / specifications
Each tablet contains 1 or 4 milligrams of methylprednisolone.
Dogs
Indication
For use in dogs as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.
Limitations
Cats
Indication
For use in cats as an anti-inflammatory agent.
Dosage
5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.
Limitations
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.
Dogs
Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations
Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.
Cats
Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Restricted During Pregnancy • Cat
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.
Dogs
Indication
Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Cats
Indication
Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Horses
Indication
Treatment of inflammation and related disorders in horses.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.
Dogs
Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Or up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.
Cats
Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.
Horses
Indication
Treatment of inflammation and related disorders.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

FDA page: Open in Animal Drugs @ FDA

Usage

Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs. Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats. Treatment of inflammation and related disorders in horses.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately. Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis,

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Diarrhea (1) • Cat Decreased appetite (1) • Cat Bloody diarrhoea (1) • Dog Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Biting - pruritus (1) • Cat Alopecia local (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat Head tilt - neurological disorder (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Other
Hiding (1) • Cat Haematuria (1) • Cat Gut sounds increased (1) • Dog Glucosuria (1) • Dog Gastroenteritis (1) • Dog
Show more (18)
Gastritis (1) • Dog Excessive chewing, licking and/or grooming (1) • Cat Eosinopenia (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Dog Digestive tract hypomotility (1) • Dog Diabetes (1) • Dog Dermatitis (1) • Cat Dental calculus (1) • Dog Dehiscence (1) • Cat Cushings disease NOS (1) • Dog Confusion (1) • Dog Bumps on skin (1) • Cat Bloody stool (1) • Dog Atopic allergy NOS (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal cytology (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Shorthair, Female, 9 year, 5.67 kilogram • Drug: MSK, Parenteral • Reactions: Diarrhea • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074908
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 5.670 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Diarrhea
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 3 year, 4.536 kilogram • Drug: MSK, Suspension, Intramuscular, Dose: 1 mL per animal • Reactions: Injection site mass NOS, Abnormal cytology • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074210
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 4.536 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Suspension
  • Dose: 1 mL per animal
Reactions Reported:
Injection site mass NOS Abnormal cytology
Outcomes: Ongoing

Dog, Catahoula Leopard Dog, Female, 6 year, 28.803 kilogram • Drug: MSK, Unknown • Reactions: Pica NOS, Diarrhea, Bloody stool, Weight loss • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071202
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 6.00 Year
  • Weight: 28.803 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Pica NOS Diarrhea Bloody stool Weight loss
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 5 year, 5.9 kilogram • Drug: MSK, Unknown • Reactions: Injection site skin change NOS, Injection site alopecia, Injection site weeping, Dehiscence, Injection site mucopurulent discharge… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-070057
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 5.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Injection site skin change NOS Injection site alopecia Injection site weeping Dehiscence Injection site mucopurulent discharge Injection site necrosis
Outcomes: Ongoing

Dog, ['Akita', 'Dog (unknown)'], Female, 6.5 year, 37.1 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Tiredness (lethargy) • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-068337
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 6.50 Year
  • Weight: 37.100 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Behavioral disorder (unspecified) Tiredness (lethargy)
Outcomes: Outcome Unknown

Dog, Beagle, Male, 4.5 year, 10.932 kilogram • Drug: MSK, Tablet, Oral • Reactions: Leucopenia NOS, Neutropenia, Eosinopenia • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-065278
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 4.50 Year
  • Weight: 10.932 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Leucopenia NOS Neutropenia Eosinopenia
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 9 year, 6.123 kilogram • Drug: MSK, Unknown • Reactions: Hyperactivity, Biting - pruritus • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-063264
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 6.123 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Hyperactivity Biting - pruritus
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.